BGI Genomics Co Ltd.

Pharma supply chains still may feel some long-lasting impacts from the proposed BIOSECURE Act, even though the bill appears unlikely to be enacted this year or perhaps ever, although it probably is to

The pending US election brings much uncertainty for the biopharma industry, but one thing is certain: firms are still going to have to worry about the BIOSECURE Act even after the presidential contest

The progress this month of a bill proposing the BIOSECURE Act in the US didn’t just spook shareholders of Chinese contract research organizations (CROs) and contract development and manufacturing orga

Pending legislation that would prohibit federal government relationships with contract service providers in certain countries and potentially restrict companies from contracting with them may have alr